Extracellular vesicles are heterogeneous populations of secreted entities categorized primarily into exosomes, microvesicles, and apoptotic bodies, each differing in size, biogenesis pathways, and molecular contents. Exosomes, typically 30-150 nm in diameter, originate from the endosomal system through inward budding of multivesicular bodies, subsequently fusing with the plasma membrane to release their cargo. Microvesicles, larger vesicles ranging up to 1,000 nm, shed directly from the plasma membrane. Understanding the precise cellular machinery orchestrating the formation and release of these vesicles is not merely an academic pursuit but a cornerstone to deciphering how cancer cells exploit EVs to manipulate their microenvironment.

Cancer cells use EVs as efficient vehicles to transfer oncogenic molecules such as proteins, lipids, mRNAs, microRNAs, and even DNA fragments to neighboring cells and distant organs. This intercellular communication mediated by EVs reprograms recipient cells, promoting tumor growth, immune evasion, angiogenesis, and metastasis. The review presents compelling evidence that EV cargo composition is dynamically modulated by the cell’s pathological state, creating a snapshot of the tumor’s molecular landscape. This selective packaging mechanism is orchestrated by various pathways, including ESCRT (endosomal sorting complex required for transport) dependent and independent mechanisms, which highlight the regulatory complexity underlying EV biogenesis.

Of particular note is the role of EVs in enabling metastatic dissemination, a primary cause of cancer mortality. Tumor-derived EVs precondition distant sites—often referred to as forming a pre-metastatic niche—by remodeling stromal and immune components to be more permissive to metastatic colonization. The cargo transported by EVs orchestrates extracellular matrix remodeling, recruitment of immunosuppressive cells, and angiogenic signaling, collectively facilitating tumor cell seeding. This insight into EV-mediated interorgan communication redefines metastasis as a multi-step process heavily reliant on vesicle trafficking, rather than solely on cell-intrinsic motility and invasion.

From a diagnostic perspective, the review emphasizes the burgeoning interest in exploiting EVs as liquid biopsy tools. Their stability in biofluids such as blood, urine, and saliva, coupled with their tumor-specific molecular signatures, positions EVs as superior candidates for non-invasive early detection, prognostic assessments, and monitoring therapeutic responses. Advanced isolation techniques and high-throughput molecular profiling technologies now enable detailed characterization of EV populations, revealing biomarker panels with remarkable sensitivity and specificity. This promises to revolutionize cancer diagnostics, particularly in malignancies currently lacking reliable screening methods.

Therapeutically, EVs offer tantalizing opportunities both as targets and delivery vehicles. Targeting EV biogenesis, release, or uptake pathways provides a novel avenue to interrupt tumor-promoting intercellular communication, potentially sensitizing tumors to conventional therapies. Conversely, engineering EVs to serve as precision delivery systems for anti-cancer drugs, nucleic acids, or immunomodulatory molecules exploits their natural biocompatibility and homing abilities. The review highlights state-of-the-art approaches in harnessing EVs for targeted therapy, including modifications to enhance tumor specificity and cargo loading efficiency, heralding a new era of personalized cancer treatment modalities.

Underlying these advancements is an expanding repertoire of cutting-edge technologies. Novel imaging techniques such as super-resolution microscopy and cryo-electron microscopy now visualize EV dynamics and structural composition with unparalleled detail. Complementary omics analyses—proteomics, transcriptomics, lipidomics—provide comprehensive insights into EV content and functional implications. Computational modeling integrated with experimental data elucidates vesicle trafficking networks and predicts therapeutic outcomes. This multidisciplinary synergy propels EV research from descriptive biology toward actionable clinical applications.

Despite the transformative potential, challenges remain. Standardization of EV isolation and characterization protocols is imperative to ensure reproducibility and comparability across studies. Heterogeneity within and between EV populations complicates the interpretation of functional roles and biomarker efficacy. Additionally, translating experimental findings into safe and efficacious clinical interventions demands rigorous validation and regulatory oversight. The review candidly discusses these limitations, advocating sustained collaborative efforts to overcome technical hurdles and ethical considerations.

The emerging narrative positions extracellular vesicles not merely as cellular byproducts but as central agents in cancer pathophysiology, diagnostics, and therapeutics. By shedding light on the molecular intricacies of EV biogenesis and cargo selection, and by elucidating their diverse oncogenic mechanisms, this body of work charts a path forward for innovative clinical strategies. Harnessing the full potential of EV biology could dramatically improve patient outcomes by enabling earlier detection, more precise monitoring, and tailored interventions.

In the broader oncology landscape, EV-based research is emblematic of a shift toward understanding cancer as a systemic disease involving complex intercellular communications rather than isolated aberrant cells. This holistic viewpoint is critical as it opens avenues not only for directly targeting tumor cells but also modulating the tumor microenvironment and systemic host responses. The interface of EV biology with immuno-oncology, for instance, is a particularly fertile area, with investigations into EV-mediated immune modulation informing novel immunotherapeutic designs.

Moreover, the scalability and versatility of EVs as therapeutics are advantageous for future clinical translation. Unlike synthetic nanoparticles, their endogenous origin confers superior biocompatibility and immune evasion capabilities. Adaptation of EVs for delivery of CRISPR-Cas systems, small interfering RNAs, or chemotherapeutic agents offers a platform adaptable to multiple cancer types and genetic contexts, addressing the inherent heterogeneity of malignancies.

Looking ahead, research is anticipated to delve deeper into the molecular determinants governing EV cargo specificity and destination targeting. Pinpointing key regulatory molecules will enable refined modulation of EV functions, either augmenting beneficial effects or blocking detrimental influences. Integrating EV studies with patient-derived organoids and in vivo models will facilitate precision medicine approaches tailored to individual tumor EV profiles.

In conclusion, the exhaustive analysis presented by Aditi and colleagues crystallizes the critical importance of extracellular vesicles in cancer biology and clinical oncology. This burgeoning field stands at the intersection of molecular cell biology, translational research, and therapeutic innovation. As we harness the intricate language of EV-mediated intercellular communication, we edge closer to breakthroughs that could transform cancer management, offering hope for more effective, less invasive, and personalized treatments. The journey from bench to bedside is underway, fueled by these diminutive yet powerful vesicles that carry the whispers and commands of cancer cells in their molecular cargo.

Subject of Research: Extracellular vesicles in cancer, including their formation, roles in oncogenesis, potential as biomarkers, and therapeutic applications.

Article Title: Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications.

Article References:
Aditi, Khajuria, A., Garima et al. Extracellular vesicles in cancer: biogenesis, oncogenic mechanisms, biomarker potential, and therapeutic applications. Med Oncol 43, 23 (2026). https://doi.org/10.1007/s12032-025-03145-x

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03145-x

Exosomes are lipid bilayer-encapsulated vesicles ranging typically from 30 to 150 nanometers in diameter. Tumor cells exploit exosomes to transfer a complex cargo that includes microRNAs (miRNAs), long noncoding RNAs (lncRNAs), circular RNAs (circRNAs), proteins, and lipids, effectively manipulating recipient cells in the microenvironment. This cargo reprograms cellular behavior by modulating critical signaling pathways such as PI3K/AKT, MAPK/ERK, Wnt/β-catenin, and NF-κB, all of which are well known for their roles in cell proliferation, survival, migration, and drug resistance. The review meticulously details how TDEs potentiate oncogenic signaling networks that facilitate tumor growth and metastasis.

Beyond their direct influence on tumor cells, TDEs substantially remodel the immune landscape of the TME. They achieve this through delivering immunoinhibitory molecules such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), which suppress the activity of cytotoxic T cells and enable immune evasion. Additionally, TDEs promote the differentiation and recruitment of immunosuppressive populations including M2-polarized macrophages and regulatory T (Treg) cells, fostering an immunosuppressive niche that protects tumor cells from immune attack. This reciprocal modulation highlights the sophisticated crosstalk facilitated by exosomes, allowing tumors to sculpt an environment conducive to their survival and metastasis.

Conversely, the review illuminates the emerging therapeutic potential of exosomes derived from immune cells or engineered vesicles. Such exosomes can deliver antitumor cytokines, tumor-associated antigenic peptides, or RNA therapeutics designed to reactivate effector immune cells or reverse immunosuppression, thereby restoring antitumor immunity. This bifunctional nature—where exosomes function both as perpetrators of immune escape and as vehicles for immune restoration—positions them at a unique intersection for innovative therapeutic strategies, including combined immunotherapies and precision medicine approaches.

Another compelling aspect elucidated in the review is the utility of exosomes as liquid biopsy biomarkers. Because the molecular content of exosomes mirrors the heterogeneity and dynamic changes within tumors, profiling exosomal RNA and protein constituents offers a noninvasive window into tumor staging, mutation status, and therapeutic responsiveness. Such liquid biopsy approaches may revolutionize cancer diagnostics by enabling real-time monitoring of disease progression and early identification of treatment resistance, potentially allowing clinicians to tailor interventions with unprecedented precision.

Mechanistically, the biogenesis and release of exosomes involve the inward budding of the endosomal membrane to form multivesicular bodies, which subsequently fuse with the plasma membrane to release exosomes into the extracellular milieu. Tumor cells exhibit aberrant regulation of this process, often amplifying exosome production to disseminate oncogenic signals widely. The selective packaging of RNA species and proteins into exosomes is mediated by specific RNA-binding proteins and sorting machinery, underscoring the highly regulated and purposeful nature of exosome-mediated communication.

Of particular interest are the noncoding RNAs—miRNAs, lncRNAs, and circRNAs—enriched in TDEs, which serve as master regulators of gene expression in recipient cells. miRNAs, for instance, can inhibit tumor suppressor gene expression or activate oncogenes once internalized. lncRNAs and circRNAs add an additional layer of epigenetic and post-transcriptional control, influencing chromatin remodeling, mRNA stability, and microRNA sponging. The review catalogs several oncogenic noncoding RNAs identified in TDEs, implicating them in promoting angiogenesis, enhancing invasiveness, and modulating chemoresistance.

The signaling pathways activated by TDE cargo are canonical nodes within cancer biology: activation of the PI3K/AKT pathway enhances survival signaling and metabolic reprogramming; MAPK/ERK cascades regulate proliferation and differentiation; Wnt/β-catenin signaling controls stemness and epithelial-mesenchymal transition (EMT); and NF-κB pathway activation fosters inflammation and resistance to apoptosis. The convergence of multiple pathways modulated by exosomal cargos reveals a network complexity that underscores the challenge of targeting these processes therapeutically but also identifies numerous potential molecular targets.

Intriguingly, the immunomodulatory roles of exosomes present both opportunities and challenges in cancer immunotherapy. By transferring immune checkpoint molecules like PD-L1, TDEs shield tumors from immune surveillance. However, exosome-based delivery systems have shown promise in enhancing immune responses—engineered exosomes loaded with tumor antigens or immunostimulatory molecules can act as vaccines, stimulating dendritic cells and cytotoxic T lymphocytes. The review forecasts that integrating exosome engineering with checkpoint blockade or adoptive cell therapies could synergize to overcome resistance and improve patient outcomes.

The authors also explore the future potential of manipulating exosome pathways in therapeutic development. Strategies may include inhibiting exosome biogenesis or release to block pro-tumorigenic signaling, engineering exosomes as delivery vehicles for gene therapies or drugs, and designing exosome-based diagnostics and prognostic tools. Such approaches envision exosomes not simply as biomarkers but as active agents in precision oncology, capable of altering tumor behavior and immune responses in a controlled manner.

Moreover, the review emphasizes the importance of understanding the heterogeneity of exosomes, as vesicles differ widely depending on their cellular origin, molecular cargo, and biophysical properties. Advances in high-throughput sequencing, proteomics, and imaging technologies are critical for unraveling this complexity, enabling the identification of exosome subpopulations with distinct functional profiles that may have differential impacts on tumor progression or therapeutic response.

As research accelerates, the clinical translation of exosome-based approaches faces hurdles such as standardized isolation techniques, scalable manufacturing, and regulatory approval pathways. Nonetheless, the review maintains an optimistic outlook, citing numerous preclinical and early clinical studies that validate the significance of exosome biology in oncology. The dual role of tumor-derived exosomes—as both villains unleashing malignant phenotypes and as potential allies delivering therapeutic payloads—captures the duality inherent in cancer’s biological complexity.

In summary, exosomes stand at the forefront of contemporary cancer research, embodying a multifaceted paradigm that intertwines tumor biology and immune regulation. This review serves as a compelling synthesis of the state-of-the-art, weaving molecular insights with clinical implications and envisaging a future where exosome-based diagnostics and therapeutics reshape the oncology landscape. By decoding the language of these diminutive vesicles, scientists are poised to unlock novel avenues for combating one of humanity’s most formidable diseases.

Subject of Research: Tumor-derived exosomes and their dual roles in cancer progression and immune modulation.

Article Title: Dual Roles of Tumor-Derived Exosomes in Cancer and Immunity

Web References:
http://dx.doi.org/10.1002/mdr2.70022

Image Credits: The authors.

Keywords: Cancer, Tumor microenvironment, Tumor-derived exosomes, Noncoding RNA, Immune modulation, Liquid biopsy, Signal transduction, Immunotherapy, Exosome engineering